Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  Alpízar Alpízar, Warner ^a,b,c   Christensen, Ib Jarle ^a   Santoni Rugiu, Eric ^d   Skarstein, Arne ^b   Ovrebo, Kjell ^b   Illemann, Martin ^a   Laerum, Ole Didrik ^a,b  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

gastric cancer; immunohistochemistry; invasion; survival; uPAR

Indexed keywords

PLASMINOGEN; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; DISTAL GASTRIC ADENOCARCINOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STROMA CELL; SURVIVAL TIME; TUMOR CELL;

ADENOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84862533497     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26417     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E,. Gastric cancer. Crit Rev Oncol Hematol 2005; 54: 209-41. (Pubitemid 40703920)
3. Forman D, Burley VJ,. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-49. (Pubitemid 44391336)
4. Lochhead P, El-Omar EM,. Gastric cancer. Br Med Bull 2008; 85: 87-100. (Pubitemid 351398296)
5. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS,. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-16. (Pubitemid 39425773)
6. Schwarz RE, Zagala-Nevarez K,. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9: 394-400. (Pubitemid 34496728)
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA,. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
8. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM,. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27-39. (Pubitemid 40044837)
9. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W,. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003; 39: 1603-9. (Pubitemid 36829201)
10. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR,. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107: 120-7. (Pubitemid 29133531)
11. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74. (Pubitemid 37328786)
12. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J,. Plasminogen activation and cancer. Thromb Haemost 2005; 93: 676-81. (Pubitemid 40485402)
13. Ploug M,. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-528. (Pubitemid 36758313)
14. Alpizar-Alpizar W, Nielsen BS, Sierra R, Illemann M, Ramirez JA, Arias A, Duran S, Skarstein A, Ovrebo K, Lund LR, Laerum OD,. Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. Int J Cancer 2010; 126: 405-15.
15. Illemann M, Bird N, Majeed A, Laerum OD, Lund LR, Dano K, Nielsen BS,. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009; 124: 1860-70.
16. Nielsen BS, Rank F, Illemann M, Lund LR, Dano K,. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007; 120: 2086-95. (Pubitemid 46555845)
17. Zhang L, Zhao ZS, Ru GQ, Ma J,. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 2006; 12: 3970-6. (Pubitemid 44097102)
18. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW,. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13: 2084-93.
19. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW,. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997; 226: 736-44; discussion 44-5.
20. Allgayer H, Babic R, Grutzner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM,. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998; 16: 62-73. (Pubitemid 28122556)
21. Zhao W, Wang X, Qu B, Huang X, Wang H,. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients. Chin Med J (Engl) 2002; 115: 702-4. (Pubitemid 34594284)
22. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S,. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94: 43-9. (Pubitemid 36575857)
23. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW,. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1: 1035-9.
24. Allgayer H, Heiss MM, Riesenberg R, Grutzner KU, Tarabichi A, Babic R, Schildberg FW,. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997; 57: 1394-9. (Pubitemid 27152567)
25. Heiss MM, Simon EH, Beyer BC, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H,. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002; 20: 2005-16. (Pubitemid 34408789)
26. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H,. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 2006; 106: 1026-35.
27. Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G,. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 233-6.
28. Ronne E, Hoyer-Hansen G, Brunner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J,. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995; 33: 199-207.
29. Laerum OD, Ovrebo K, Skarstein A, Christensen IJ, Alpízar- Alpízar W, Helgeland L, Danø K, Nielsen BS, Illemann M,. Prognosis in adenocarcinomas of lower esophagus, gastro-esophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer, in press (DOI: 10.1002/ijc.26382).
30. Lin D, Wei L, Ying Z,. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557-72.
31. Yu W, Kim J, Ossowski L,. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 767-77. (Pubitemid 27200676)
32. Aguirre Ghiso JA,. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002; 21: 2513-24. (Pubitemid 34438104)
33. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L,. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-95. (Pubitemid 36373662)
34. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L,. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1: 445-57. (Pubitemid 41039125)
35. Aguirre Ghiso JA, Kovalski K, Ossowski L,. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147: 89-104.
36. Gardsvoll H, Ploug M,. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007; 282: 13561-72. (Pubitemid 47100512)
37. Madsen CD, Sidenius N,. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 2008; 87: 617-29.
38. Allgayer H, Aguirre-Ghiso JA,. The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 2008; 116: 602-14.
39. Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M,. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Br J Cancer 2009; 100: 153-9.
40. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, Harris AL,. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-41. (Pubitemid 34517650)
41. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N,. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-74. (Pubitemid 29252303)
42. Grondahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E, Dano K, Klijn JG, Brunner N, Foekens JA,. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079-87.
43. Almasi CE, Hoyer-Hansen G, Christensen IJ, Pappot H,. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS 2009; 117: 755-61.
44. Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R, Ciavarella D, Lo Muzio L, Fazioli F,. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer 2008; 8: 220.
45. Kessenbrock K, Plaks V, Werb Z,. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
46. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J,. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J Pathol 2000; 190: 190-5. (Pubitemid 30082493)
47. Biswas SK, Sica A, Lewis CE,. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008; 180: 2011-7.
48. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A,. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
49. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N,. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003; 23: 5015-22. (Pubitemid 38182119)
50. Algood HM, Cover TL,. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev 2006; 19: 597-613. (Pubitemid 44582973)